報價延遲最少15分鐘:2025/11/05 08:43 EST
盤前時段
|
||||
|
2.62 
|
|
|
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
2.53
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.25/-0.46
|
|
企業價值
104.36M
|
| 資產負債 |
|
每股賬面淨值
0.28
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
報價延遲最少15分鐘：2025/11/05 08:43 EST
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Anebulo Pharmaceuticals Inc is a clinical-stage biotechnology company focused on developing treatments for cannabinoid overdose and substance addiction. Its principal product candidate, ANEB-001 (Selonabant), is designed to rapidly counteract the negative effects of cannabis toxicity, including unintentional cannabis poisoning and acute cannabinoid intoxication. The company is focusing on addressing the unmet medical needs in the treatment of cannabinoid toxicity through various therapies. Anebulo Pharmaceuticals operates in one segment, exclusively in the United States. |
